Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

467
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
467
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.

bioRxiv : the preprint server for biology·2026
Same author

Industrial Adoption of Carbon Nanotubes.

Nano letters·2026
Same author

Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature.

Nature nanotechnology·2025
Same author

Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids.

Nature biomedical engineering·2025
Same author

Tumor microenvironment-targeted PROTAC nanoparticle self-assembly broadly predicted by structural descriptors.

Science advances·2025
Same author

Apparent Diffusion Coefficient Magnetic Resonance Imaging as a Predictive Biomarker for Hypoxia, Treatment De-escalation, and Recurrence in Human Papillomavirus-Associated Oropharyngeal Cancer.

International journal of radiation oncology, biology, physics·2025

相关实验视频

Updated: May 31, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

795

微环境激活的CAR T细胞提高了固体瘤的疗效,没有毒性.

Kristen C Vogt1,2,3, Pedro C Silberman1,2,4, Qianqian Lin1,2,5

  • 1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Science advances
|January 22, 2025
PubMed
概括

工程T细胞 (MEAT细胞) 只有在遇到瘤新血管时,才能表达仿真抗原受体 (CARs). 这种有针对性的方法可以在固体瘤治疗中预防神经毒性,同时保持疗效.

更多相关视频

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.0K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.0K

相关实验视频

Last Updated: May 31, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

795
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.0K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.0K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法在固体瘤治疗中面临挑战,因为它针对正常组织的共享抗原.
  • 准GD2的CAR T细胞通过在正常脑组织上识别GD2引起致命的神经毒性.

研究的目的:

  • 为改造 CAR T 细胞,提高对固体瘤的选择性,最大限度地减少非向性毒性.
  • 开发一种由瘤微环境特定目标激活的有条件CAR表达系统.

主要方法:

  • 设计了一种合成的Notch受体,用于有条件的CAR表达.
  • 设计的T细胞 (MEAT细胞) 在与瘤新血管的标志物P-选择素结合时表达CARs.
  • 在临床前模型中评估MEAT细胞的疗效和毒性.

主要成果:

  • 肉细胞通过限制CAR表达和T细胞透到大脑中来预防神经毒性.
  • 对固体瘤保持显著的抗瘤疗效.
  • 证明了瘤透MEAT细胞的强化持久性和代谢适应性.

结论:

  • 通过合成的Notch受体进行条件CAR表达,可以提高CAR T细胞在固体瘤中的安全性和有效性.
  • 这种方法通过确保特定于癌细胞的向来扩大可向的固体瘤抗原的范围.
  • 为开发更安全的CAR T细胞疗法用于各种固体恶性瘤提供了一个多功能平台.